Difference between revisions of "Profiles"

From QIBA Wiki
Jump to navigation Jump to search
Line 6: Line 6:
 
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Clinically Feasible (formerly Technically Confirmed) Profiles===
 
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Clinically Feasible (formerly Technically Confirmed) Profiles===
  
 +
*[[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf|MR Elastography of the Liver 2022-02-14]]
  
*[[Media:Supplement QIBA AmyloidPET 3Jun2022 TechnicallyConfirmed.pdf| PET Amyloid 2022-06-03]]
+
*[[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2018.11.18-clean-4.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2018-11-18]]
  
*[[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf| MR Elastography of the Liver 2022-02-14]]
+
*[[Media:QIBACTVol TumorVolumeChange(2022)-20220721.pdf|CT Tumor Volume Change for Advanced Disease 2022-07-21 Streamlined Profile]]
 +
:*32 pages including Conformance Checklists
  
* [[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2018.11.18-clean-4.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2018-11-18]]
+
*[[Media:Supplement QIBA AmyloidPET 3Jun2022 TechnicallyConfirmed.pdf|PET Amyloid 2022-06-03]]
  
* [[Media:QIBACTVol TumorVolumeChange(2022)-20220721.pdf|CT Tumor Volume Change for Advanced Disease 2022-07-21 Streamlined Profile]]
+
*[[Media:QIBA FDG-PET Profile v113.pdf|PET/CT FDG SUV for Response to Cancer Therapy 2016-11-18]]
:* 32 pages including Conformance Checklists
 
 
 
* [[Media:QIBA FDG-PET Profile v113.pdf|PET/CT FDG SUV for Response to Cancer Therapy 2016-11-18]]
 
 
:*[[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 2014-12]]
 
:*[[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 2014-12]]
  
Line 45: Line 44:
 
:*[[Media:SWS Checklists-Appendix E-04.25.2022.xlsx|Appendix E: SWS Checklists]] (updated April 25, 2022)
 
:*[[Media:SWS Checklists-Appendix E-04.25.2022.xlsx|Appendix E: SWS Checklists]] (updated April 25, 2022)
  
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles ===
+
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===
  
 
'''Please submit comments using the '''[https://forms.gle/bPzUAuLKJnHYGbVS7 '''online form''']
 
'''Please submit comments using the '''[https://forms.gle/bPzUAuLKJnHYGbVS7 '''online form''']
Line 75: Line 74:
  
  
==== See Also====
+
====See Also====
 
*[[How to use QIBA Profiles]]
 
*[[How to use QIBA Profiles]]
 
*[[Committees|Biomarker Committee]] pages may also have links to DRAFT Profile documents for the next Stage.
 
*[[Committees|Biomarker Committee]] pages may also have links to DRAFT Profile documents for the next Stage.

Revision as of 18:50, 19 October 2022

Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.

Profiles may be of use at any Stage.

Stage 3: Clinically Feasible (formerly Technically Confirmed) Profiles

  • 32 pages including Conformance Checklists

Stage 2: Consensus Profiles

Stage 1: Public Comment Profiles

Please submit comments using the online form


Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations.


Format for Citing Profiles

Cite QIBA Profile documents as:

Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Version. Profile Stage. Date. Available from: URL

Example:

QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles


Statements of Endorsement


See Also